ALKERMES | ALKS - Interest Expense On Debt

ALKERMES reported $4.77M in Interest Expense on Debt for its fourth fiscal quarter of 2022.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

API Features Documentation Interested? Click here to contact us
Please Paste this Code in your Website
width
height
 Preview
Interest Expense On Debt Change
Amgen AMGN:US USD 415M 47M
Biogen BIIB:US USD 54.8M 5.1M
Biomarin Pharmaceutical BMRN:US USD 3.63M 1.05M
Bristol Myers Squibb BMY:US USD 294M 5M
Coherus Biosciences CHRS:US USD 9.38M 1.84M
Gilead Sciences GILD:US USD 227M 2M
IONIS PHARMACEUT IONS:US USD 1.73M 408K
JAZZ PHA JAZZ:US USD 81.22M 2.52M
Marinus Pharmaceuticals MRNS:US USD 3.69M 1.06M
Nektar Therapeutics NKTR:US USD 7.2M 248K
Neurocrine Biosciences NBIX:US USD 1.1M 100K
Pfizer PFE:US USD 313M 2M
Regeneron Pharmaceuticals REGN:US USD 17.4M 2.1M
Revance Therapeutics RVNC:US USD 3.75M 3.16M
Teva Pharmaceutical Industries TEVA:US USD 237M 7M
Vertex Pharmaceuticals VRTX:US USD 11.6M 2.1M